Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 3Advanced Solid Tumor 3Stomach Neoplasms 2Lung Neoplasms 2Cholangiocarcinoma 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous NSCLC 1Solid Tumor 1SCLC 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1High-Risk Resectable NSCLC 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × High-Risk Resectable NSCLC × sintilimab × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡